Scandinavian ChemoTech will launch a feasibility study to investigate the possibility of starting a clinical program focusing on pancreatic cancer
ChemoTech's Board of Directors has today decided to begin a feasibility study along with a group of leading specialists in pancreatic cancer in the US and Europe in order to create an international clinical collaboration.Last year, ChemoTech's technology for bone cancer was able to treat its first patient with deep-seated tumours. As the pancreas is also a deep-seated organ, the Company has now decided that this cancer indication may also be suitable for treatment with ChemoTech's technology and should thus be seen as a prioritised indication. Today, the conditions for patients with